Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002

March 23, 2011 By Bio-Medicine.Org

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ — NephRx
Corporation today announced issuance of a new U.S. patent for its
novel peptide NX002, which currently is in preclinical development
for the treatment of oral mucositis.  Previously, NephRx
reported that NX002 had demonstrated significant efficacy when
tested in well-validated animal models of oral mucositis.
 Mucositis is a debilitating and often dose-limiting condition
that affects more than 400,000 cancer patients who receive
chemotherapy or radiation therapy in the U.S. each year.
 Current treatment options are limited.

“Issuance of this most recent patent further confirms the
promising utility of NX002 as a potential treatment for oral
mucositis,” said James Koziarz, President and CEO of NephRx.
 “Mucositis is a painful and debilitating side effect of
cancer therapy that can be dose-limiting, jeopardizing patients’
chances for successful treatment.  We look forward to
advancing the detailed NX002 toxicity studies needed to initiate
the mucositis clinical program for NX002.”

NX002 is a peptide derived from the naturally occurring growth
factor AMP-18, which has been shown to stimulate the growth of
epithelial cells and to promote mucosal wound healing after
injury.  Its multiple biological properties include the
ability to protect cells from injury, stimulate cell growth and
migration, and increase the accumulation of proteins that bind
cells together.  In a study in a well-validated mucositis
model, animals treated with NX002 had reduced levels of oral
ulceration and a more rapid recovery, with no evidence of toxicity.
 NephRx has begun the preclinical toxicology studies of NX002
needed to initiate mucositis clinical trials targeted for late 2011
or early 2012.

The U.S. Patent and Trademark office issued Patent No. 7910543,
“Control of growth and repair of gastro-intestinal tissues by
gastrokines and inhibitors.”  Rights to this patent,

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech